Clinicians must maintain awareness of the latest clinical trials ongoing in the management of multiple myeloma, including those of bispecific antibody therapies targeting BCMA.
Selected Clinical Studies of BCMA-Directed Bispecific Antibody Therapies in Multiple Myeloma
| Treatment | Title | Link |
| Linvoseltamab (REGN5458)A | Phase 1/2 FIH Study of REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Patients With Relapsed or Refractory Multiple Myeloma | https://clinicaltrials.gov/study/NCT03761108 |
| Phase 1b Study of REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) Plus Other Cancer Treatments for Patients With Relapsed/Refractory Multiple Myeloma | https://clinicaltrials.gov/study/NCT05137054 | |
| Compassionate Use (CU) of REGN5458 for Patients With Relapsed or Refractory Multiple Myeloma (MM) | https://clinicaltrials.gov/study/NCT05164250 | |
| An Open-label, Randomized, Phase 3 Study of Linvoseltamab (REGN5458; Anti- BCMA x Anti-CD3 Bispecific Antibody) Versus the Combination of Elotuzumab, Pomalidomide, and Dexamethasone (EPd), in Patients With Relapsed/Refractory Multiple Myeloma (LINKER-MM3) | https://clinicaltrials.gov/study/NCT05730036 | |
| A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment (LINKER-MM4) | https://clinicaltrials.gov/study/NCT05828511 | |
| EMB-06 | A First-in-human, Phase I/II, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of EMB-06 in Patients With Relapsed or Refractory Multiple Myeloma | https://clinicaltrials.gov/study/NCT04735575 |
| Elranatamab (PF-06863135) | MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma | https://clinicaltrials.gov/ct2/show/NCT05090566 |
| MagnetisMM-8: Study Of Elranatamab (PF-06863135) Monotherapy in Chinese Participants With Refractory Multiple Myeloma | https://clinicaltrials.gov/ct2/show/NCT05228470 | |
| MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma (MAGNETISMM-5) | https://clinicaltrials.gov/ct2/show/NCT05020236 | |
| Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135) | https://clinicaltrials.gov/ct2/show/NCT05238311 | |
| Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant (MagnetisMM-7) | https://clinicaltrials.gov/ct2/show/NCT05317416 | |
| A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment (MagnetisMM-9) | https://clinicaltrials.gov/ct2/show/NCT05014412 | |
| ABBV-383 | A Phase 3, Multicenter, Randomized, Open Label Study of ABBV-383 Compared With Standard Available Therapies in Subjects With Relapsed or Refractory Multiple Myeloma (3L+ RRMM Monotherapy Study) | https://clinicaltrials.gov/study/NCT06158841 |
| A Dose Escalation and Expansion Study of ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma | https://clinicaltrials.gov/study/NCT05259839 | |
| A Multicenter, Phase 1b, Open-label Study of ABBV-383 Administered Subcutaneously in Subjects With Relapsed or Refractory Multiple Myeloma | https://clinicaltrials.gov/study/NCT06223516 | |
| A Multicenter, Phase 1b, Open-label Study to Evaluate Dose Optimization Measures and Safety of ABBV-383 in Subjects With Relapsed or Refractory Multiple Myeloma | https://clinicaltrials.gov/study/NCT05650632 | |
| Teclistamab (JNJ-64007957) | A Phase 3 Randomized Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide | https://clinicaltrials.gov/study/NCT05572515 |
| Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation – MajesTEC-4 | https://clinicaltrials.gov/study/NCT05243797 | |
| A Phase 2 Study of Teclistamab in Combination With Daratumumab or Lenalidomide in Elderly Patients With Newly Diagnosed Multiple Myeloma | https://clinicaltrials.gov/study/NCT05572229 | |
| Cevostamab | A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (CAMMA 1) | https://clinicaltrials.gov/study/NCT04910568 |
| Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) | https://clinicaltrials.gov/study/NCT03275103 | |
| A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma (CAMMA 2) | https://clinicaltrials.gov/study/NCT05535244 | |
| Cevostamab Following CAR T Cell Therapy for RRMM | https://clinicaltrials.gov/study/NCT05801939 | |
| A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) | https://clinicaltrials.gov/study/NCT05927571 |
